# Pulse Biosciences to Present at the BofA Securities 2026 Healthcare Conference
Canonical URL: https://biopharmsignal.com/news/PLSE/pulse-biosciences-to-present-at-the-bofa-securities-2026-healthcare-conference
Ticker: PLSE
Company: Pulse Biosciences
Source: Pulse Biosciences
Published: 2026-05-08 11:00 EST
Original Source URL: https://investors.pulsebiosciences.com
## Summary

HAYWARD, Calif. --(BUSINESS WIRE)--May 8, 2026-- Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced plans to participate in the upcoming BofA Securities 2026 Healthcare Conference in Las Vegas,

## Article Body
HAYWARD, Calif. --(BUSINESS WIRE)--May 8, 2026-- Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced plans to participate in the upcoming BofA Securities 2026 Healthcare Conference in Las Vegas,
## Recent Company News
- 2026-05-27 20:05 EST — [Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026](https://biopharmsignal.com/news/PLSE/pulse-biosciences-to-present-at-the-goldman-sachs-47th-annual-global-healthcare-conference-2026) — Source: Pulse Biosciences
- 2026-05-12 11:00 EST — [ATM Equity Purchases by Pulse Biosciences’ Co-Chairmen Total Approximately $13.3 Million](https://biopharmsignal.com/news/PLSE/atm-equity-purchases-by-pulse-biosciences-co-chairmen-total-approximately-13-3-million) — Source: Pulse Biosciences
- 2026-05-08 11:00 EST — [Pulse Biosciences to Present at the BofA Securities 2026 Healthcare Conference](https://biopharmsignal.com/news/PLSE/pulse-biosciences-to-present-at-the-bofa-securities-2026-healthcare-conference) — Source: Pulse Biosciences
- 2026-05-04 11:00 EST — [Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results](https://biopharmsignal.com/news/PLSE/pulse-biosciences-reports-business-updates-and-first-quarter-2026-financial-results) — Source: Pulse Biosciences
- 2026-04-25 17:00 EST — [Pulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse™ Cardiac Catheter System at Heart Rhythm 2026](https://biopharmsignal.com/news/PLSE/pulse-biosciences-presents-positive-outcomes-in-late-breaking-updated-data-from-npulsetm-cardiac-catheter-system-at-heart-rhythm-2026) — Source: Pulse Biosciences
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)